Bausch + Lomb has acquired the assets and U.S. rights for Zirgan (ganciclovir 0.15% gel) from Sirion Therapeutics. Zirgan was approved by the FDA in 2009 as a topical antiviral for the treatment of acute herpetic keratitis (corneal ulcers). In 2007, Sirion Therapeutics licensed the Zirgan product technology and trademark from Laboratoires Théa, headquartered in France, for the U.S. market. Ganciclovir gel, under the name Virgan, has been the standard-of-care therapy in Europe for more than a decade, Bausch + Lomb says.
SECO International has changed its 2011 meeting dates—it will now be held March 2 through March 6, 2011. The event was originally scheduled for early February, but feedback from attendees and exhibitors, some of whom cited this year’s severe weather, indicated that March dates would be more feasible. SECO will also move to Building C of the Georgia World Congress Center.
TLC Vision has emerged from bankruptcy as a private company owned by the investment firms Charlesbank Capital Partners and H.I.G. Capital. The company’s reorganization plan provides for payment in full of all outstanding amounts owed to TLC’s senior secured lenders, as well as $9 million in cash and $3 million in a promissory note to pay unsecured creditors. A new board of directors has also been named; the previous directors resigned as part of the reorganization.